In another study, S100A13 was identified as a key player in the resistance of Cutaneous Malignant Melanoma (CMM) to dacarbazine therapy [167], suggesting multiple roles of S100A13 in melanoma metastasis and drug resistance. The gene discussed is S100A13; the disease is cutaneous melanoma.